<MedlineCitation Status="Completed">
<MedlineID>10011837</MedlineID>
<PMID>217486</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-8993</ISSN>
<JournalIssue>
<Volume>160</Volume>
<Issue>3</Issue>
<PubDate>
<Year>1979</Year>
<Month>Jan</Month>
<Day>19</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Differential effect of reserpine on dopaminergic receptor function in rat substantia nigra and caudate nucleus.</ArticleTitle>
<Pagination>
<MedlinePgn>553-8</MedlinePgn>
</Pagination>
<AuthorList>
<Author>
<LastName>Tonon</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author>
<LastName>Saiani</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author>
<LastName>Spano</LastName>
<ForeName>P F</ForeName>
<Initials>PF</Initials>
</Author>
<Author>
<LastName>Trabucchi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Brain Res</MedlineTA>
<NlmUniqueID>0045503</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Dopamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>102-32-9</RegistryNumber>
<NameOfSubstance>3,4-Dihydroxyphenylacetic Acid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>25614-03-3</RegistryNumber>
<NameOfSubstance>Bromocriptine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-55-5</RegistryNumber>
<NameOfSubstance>Reserpine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>51-61-6</RegistryNumber>
<NameOfSubstance>Dopamine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>52-86-8</RegistryNumber>
<NameOfSubstance>Haloperidol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>60-92-4</RegistryNumber>
<NameOfSubstance>Cyclic AMP</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 4.6.1.1</RegistryNumber>
<NameOfSubstance>Adenylate Cyclase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>3,4-Dihydroxyphenylacetic Acid</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adenylate Cyclase</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Bromocriptine</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Caudate Nucleus</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName>enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Cyclic AMP</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Dopamine</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Haloperidol</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Rats</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Receptors, Dopamine</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Reserpine</DescriptorName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Substantia Nigra</DescriptorName>
<QualifierName MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName>enzymology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
